Minitouch has been rigorously tested in FDA clinical trials in the U.S. and over a decade of real-world use in the U.K., confirming its exceptional safety profile, minimal complications, and high patient satisfaction. Unlike older endometrial ablation devices that rely on high-temperature energy, uterine distension, or mechanical pressure, Minitouch uses a gentle, low-temperature electromagnetic field to minimize risks while ensuring consistent, long-term results.
Before receiving FDA approval, Minitouch underwent a controlled, multicenter clinical trial to evaluate its safety and effectiveness. The results demonstrated:
These results confirm that Minitouch provides a safer alternative to hysterectomy and second-generation ablation devices while maintaining high patient satisfaction and long-term success.
Minitouch has been used in the United Kingdom for over a decade, with thousands of successful procedures performed in real-world clinical settings.
Key findings from the U.K. experience include:
This extensive real-world experience reinforces Minitouch’s proven track record of safety and reliability.
and an impeccable safety record, Minitouch sets a new standard for safe, effective, and patient-friendly endometrial ablation.
Minitouch’s 3rd-Generation Technology empowers OB/GYNs to deliver effective, gentle care—no anesthesia, no cervical dilation, just life-changing outcomes in minutes.
© 2025 uinoted.com | All Rights Reserved.